We are trying to design Mesoporous Silica Nanoparticles for breast cancer treatment by PhotoDynamic Therapy.
And we are challenging with a question that Which ligand should we add onto the particle for attaching only breast cancer cells when the particles are added into the tumor cells directly by the vaccine (intra-tumoral injection).
Our ligand choice is Anti-HER2 antibody, HA.
We try to research that it is a good choice for us.
#Ligand #HyaluronicAcid #DrugDelivery #BreastCancer #PhotodynamicTherapy #SilicaNanoParticles #Ligand #Antibody #IntraTumoralInjection
If you administrated your nanoparticles locally (intrtumor injection) , I think you needn't design the specificities or targeted strategies of your drug delivery. Because from tumor biology perspectives, the aggressive cancer cells are always infiltrating into surrounding microenvironment with some physical or immune barriers. Therefore, even if you treated the cancer cells by monoantibodies, you can't kill the tumor totally.
However, if your delivery strategies are intravenous injection, tageted therapy is the most important principle that you must take into considerations. So, in this context, my suggestions are that what kind of tumor you are goning to treat decides what antibodies you are attaching. As is known to all, breast cancer has less than three kinds: ER+, HER2+, and trible negative (luminal). I suggest you could widen your antibody choices for HER2+ breast cancers. Do the nanoparticles have a good ability to load Antibodies? What's the relationship between your breast cancer cells with your mesoporous NPs, drugs, and Antibodies? ...
- Badges
- Science topic
- Similar topics
- Physics
- Condensed Matter Physics
- Solid State Physics
- PEAKS